Table 1.
Patient, tumor, and radiation characteristics.
| No. (%), n = 166 | Median (range) | |
|---|---|---|
| Age, years | 75 (23–95) | |
| Sex | ||
| Male | 68 (41.0) | |
| Female | 98 (59.0) | |
| Primary tumor site | ||
| Lung | 154 (92.8) | |
| Gastrointestinal | 8 (4.8) | |
| Thyroid | 1 (0.6) | |
| Genitourinary | 3 (1.8) | |
| Histology | ||
| Adenocarcinoma | 152 (91.6) | |
| Squamous cell carcinoma | 9 (5.4) | |
| Other | 5 (3.0) | |
| Tumor size, cm | 2.0 (0.6–5.6) | |
| <2.0 cm | 82 (49.7) | |
| ≥2.0 cm or <3.0 cm | 42 (25.5) | |
| ≥3.0 cm or <4.0 cm | 25 (15.2) | |
| ≥4.0 cm | 16 (9.7) | |
| AKT1 mutation status | ||
| Present | 1 (0.6) | |
| Absent | 165 (99.4) | |
| EGFR mutation status | ||
| Present | 35 (21.1) | |
| Absent | 131 (78.9) | |
| PIK3CA mutation status | ||
| Present | 6 (3.6) | |
| Absent | 160 (96.4) | |
| SBRT total dose, Gy | 48 (30–70) | |
| SBRT total fractions | 4 (3–10) | |
| BED,*Gy | 106 (48–180) | |
| <100 Gy | 41 (24.7) | |
| ≥100 Gy | 125 (75.3) | |
| Local failure status | ||
| No | 150 (90.4) | |
| Yes | 16 (9.6) | |
| Survival status | ||
| Alive | 114 (68.7) | |
| Dead | 52 (31.3) | |
Abbreviations: BED = biologically effective dose; Gy = Gray; SBRT = stereotactic body radiation therapy.
*
BED based on alpha/beta of 10.